MedicinMan Deck & Pricing Stack Revised_Page_07
Saturday, August 29, 2026
25.6
C
Bengaluru
Hot topics
Consumer Experience in Pharmaceutical Industry
A wholesome view of the brand shapes a customer’s...
DeepSeek – A Precursor to Patent Disruption?
The rise of open-source platforms, such as China’s DeepSeek...
What Leadership is Not! Position, Authority, or Activity
Leadership is not Measured by Position, Authority, or Activity.
It...
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
Hot topics
Navigating India’s Diverging Health Landscape and Field Force Optimisation
India’s health map is splitting into two distinct opportunity...
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
India’s Patent Revocations: Strengthening Access and Challenging Evergreening
The Indian Patent Office’s recent decision to revoke Novartis’...
Culture and Resistance to Change – A Pharma SFE Adoption Case Study
As an MNC Head, I was one among the...
Why Private Equity is the New Kingmaker in Pharma & MedTech
The PE Playbook: Why Private Equity is the New...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Newsletter
Get important news delivered directly to your inbox and stay connected!